Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Daejin | - |
dc.contributor.author | Lee, Jongsoo | - |
dc.contributor.author | Bae, InHwan | - |
dc.contributor.author | Kim, Minyoung | - |
dc.contributor.author | Huh, Youngho | - |
dc.contributor.author | Choi, Jaehyuk | - |
dc.contributor.author | Bae, Sungmin | - |
dc.contributor.author | Choi, In Young | - |
dc.contributor.author | Kim, Ha Hyung | - |
dc.contributor.author | Kim, Dae Kyong | - |
dc.date.accessioned | 2021-12-08T03:40:20Z | - |
dc.date.available | 2021-12-08T03:40:20Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1045-1056 | - |
dc.identifier.issn | 1095-8320 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/52380 | - |
dc.description.abstract | FGF21 (Fibroblast Growth Factor 21), which is expressed in the liver, adipose tissue, and pancreas, has been widely known as a therapeutic candidate for metabolic diseases. Though FGF21 is crucial to glucose, lipid, and energy homeostasis, it is not straightforward to develop a new drug with FGF21 due to its short half-life in serum. Here, we derived a novel long-acting FGF21 (LAPS-FGF21), which is chemically conjugated to the human IgG4 Fc fragment for longer half-life in serum. The recombinant human IgG4 Fc fragment and FGF21 were prepared by the refolding of inclusion body and periplasmic expression in Escherichia coli overexpression systems, respectively. The efficacy study of LAPS-FGF21 in a Diet-Induced Obesity (DIO) mouse model revealed that LAPS-FGF21 reduced body weight effectively accompanied by improved glucose tolerance in a dose-dependent manner. The administration of LAPS-FGF21 also improved the blood profiles with a significant reduction in cholesterol and triglyceride levels. Additionally, the pharmacokinetic (PK) studies of LAPS-FGF21 using normal ICR mice demonstrated that the half-life of LAPS-FGF21 was approximately 64-fold longer than FGF21. Taken together, the LAPS-FGF21 could be a feasible drug candidate with excellent bodyweight loss efficacy and longer dosing interval by half-life increase in serum. © 2020 International Alliance for Biological Standardization | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Academic Press | - |
dc.title | Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.biologicals.2020.11.005 | - |
dc.identifier.bibliographicCitation | Biologicals, v.69, pp 49 - 58 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000768552200001 | - |
dc.identifier.scopusid | 2-s2.0-85096985933 | - |
dc.citation.endPage | 58 | - |
dc.citation.startPage | 49 | - |
dc.citation.title | Biologicals | - |
dc.citation.volume | 69 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Fibroblast growth factor 21 (FGF21) | - |
dc.subject.keywordAuthor | Human IgG4 fc | - |
dc.subject.keywordAuthor | Long-acting FGF21 (LAPS-FGF21) | - |
dc.subject.keywordAuthor | Obesity | - |
dc.subject.keywordPlus | FIBROBLAST GROWTH FACTOR-21 | - |
dc.subject.keywordPlus | BETA-KLOTHO | - |
dc.subject.keywordPlus | INSULIN | - |
dc.subject.keywordPlus | BIOLOGY | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.